During the past decade, CHU Tours conducted 373 clinical trials. In the 10-year time frame, 373 clinical trials started and 34 clinical trials were completed, i.e. on average, 9.1% percent of trials that started reached the finish line to date. In the past 5 years, 206 clinical trials started and 25 clinical trials were completed. i.e. 12.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Tours" #1 sponsor was "University Hospital, Tours" with 38 trials, followed by "University Hospital, Brest" with 30 trials sponsored, "Nantes University Hospital" with 27 trials sponsored, "UNICANCER" with 22 trials sponsored and "Intergroupe Francophone de Cancerologie Thoracique" with 22 trials sponsored. Other sponsors include 418 different institutions and companies that sponsored additional 177 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Tours" #1 collaborator was "Ministry of Health, France" with 16 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 10 trials as a collaborator, "University Hospital, Tours" with 10 trials as a collaborator, "Eli Lilly and Company" with 6 trials as a collaborator and "Hoffmann-La Roche" with 5 trials as a collaborator. Other collaborators include 310 different institutions and companies that were collaborators in the rest 257 trials.

According to Clinical.Site data, the most researched conditions in "CHU Tours" are "Multiple Myeloma" (16 trials), "Amyotrophic Lateral Sclerosis" (9 trials), "Breast Cancer" (9 trials), "Chronic Lymphocytic Leukemia" (9 trials) and "Prostate Cancer" (7 trials). Many other conditions were trialed in "CHU Tours" in a lesser frequency.

Most popular intervention types in "CHU Tours" are "Drug" (265 trials), "Other" (114 trials), "Procedure" (68 trials), "Device" (65 trials) and "Biological" (30 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (46 trials), "Rituximab" (11 trials), "Dexamethasone" (9 trials), "Lenalidomide" (8 trials) and "fluorouracil" (8 trials). Other intervention names were less common.

The vast majority of trials in "CHU Tours" are 494 trials for "All" genders, 45 trials for "Female" genders and 19 trials for "Male" genders.

Currently, there are 220 active trials in "CHU Tours". 14 are not yet recruiting, 142 are recruiting, 61 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 247 completed trials in CHU Tours, undefined suspended trials, and 37 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Tours, 22 "Phase 1" clinical trials were conducted, 95 "Phase 2" clinical trials and 165 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 131 trials that are defined as “Not Applicable".

CHU Tours has several departments that took part in Clinical trials: "Service d'Hépatogastro-entérologie CHRU de TOURS" - 2 trials